Drug Profile
AZD 1080
Alternative Names: AZD1080Latest Information Update: 12 Feb 2008
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antidementias
- Mechanism of Action Glycogen synthase kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 12 Feb 2008 Discontinued - Phase-I for Alzheimer's disease in United Kingdom (unspecified route)
- 06 Aug 2004 Preclinical trials in Alzheimer's disease in United Kingdom (unspecified route)